Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1Phase 2 1

Status

Completed 2Active not recruiting 2

Sponsor Class

OTHER 7INDUSTRY 4FED 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4Other hematologic neoplasm 2

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 14Lymphoma, Mantle-Cell 10Waldenstrom Macroglobulinemia 9Lymphoma, B-Cell, Marginal Zone 9Recurrence 8Lymphoma, Large B-Cell, Diffuse 8Lymphoma, Follicular 7Lymphoma, B-Cell 4Lymphoma 4B-cell Malignancies 3Lymphoma, Non-Hodgkin 2Leukemia 2Hematologic Neoplasms 2Neoplasms 1Myelodysplastic Syndromes 1Mature B-Cell Malignancies 1Lymphoma, T-Cell 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Hematologic Diseases 1

Interventions

Rituximab 63Cyclophosphamide 37Brentuximab Vedotin 22Bendamustine Hydrochloride 22pembrolizumab 20fludarabine 20Gemcitabine 20Doxorubicin 20Prednisone 19ibrutinib 17Vincristine 16obinutuzumab 14Lenalidomide 13Nivolumab 10Rifampin 8parsaclisib 7duvelisib 7atezolizumab 7Vorinostat 7Dexamethasone 7Azacitidine 7spartalizumab 6loncastuximab tesirine 6MLN 8237 6venetoclax 5ixazomib 5glofitamab 5fludarabine phosphate 5durvalumab 5acalabrutinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma × zanubrutinib × Clear all
NCT04662255 2026-05-15

BRUIN-MCL-321

Eli Lilly and Company

Phase 3 Active not recruiting
500 enrolled
Lymphoid

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT05952037 2026-01-02

A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia

BeOne Medicines

Phase 2 Active not recruiting
114 enrolled
Lymphoid

Lymphoma, Waldenstrom Macroglobulinemia

NCT02569476 2024-10-26

BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies

BeiGene

Phase 1 Completed
119 enrolled 34 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma

NCT02795182 2022-07-01

Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies

BeiGene

Phase 1 Completed
75 enrolled 17 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡